Comprehensive multimodal management of borderline resectable pancreatic cancer:Current status and progress  

作　　者：Hong-Yu Wu Jin-Wei Li Jin-Zheng Li Qi-Long Zhai Jing-Yuan Ye Si-Yuan Zheng Kun Fang 

机构地区：[1]Department of Hepatobiliary Surgery,The Second Affiliated Hospital of Chongqing Medical University,Chongqing 400010,China [2]Department of Neurosurgery,The Fourth Affiliated Hospital of Guangxi Medical University,Liuzhou 545000,Guangxi Province,China [3]Department of Surgery,Yinchuan Maternal and Child Health Hospital,Yinchuan 750000,Ningxia,China

出　　处：《World Journal of Gastrointestinal Surgery》2023年第2期142-162,共21页世界胃肠外科杂志（英文版）（电子版）

摘　　要：Borderline resectable pancreatic cancer(BRPC)is a complex clinical entity with specific biological features.Criteria for resectability need to be assessed in combination with tumor anatomy and oncology.Neoadjuvant therapy(NAT)for BRPC patients is associated with additional survival benefits.Research is currently focused on exploring the optimal NAT regimen and more reliable ways of assessing response to NAT.More attention to management standards during NAT,including biliary drainage and nutritional support,is needed.Surgery remains the cornerstone of BRPC treatment and multidisciplinary teams can help to evaluate whether patients are suitable for surgery and provide individualized management during the perioperative period,including NAT responsiveness and the selection of surgical timing.

关 键 词：Borderline resectable pancreatic cancer Neoadjuvant therapy RESECTABILITY SURGERY Multimodality treatment Multidisciplinary teams 

分 类 号：R735.9[医药卫生—肿瘤]